In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Janssen) have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents, including the IL-17 inhibitors—Novartis’s Cosentyx in 2015, Eli Lilly’s Taltz in 2016, and Valeant’s Siliq in 2017—and the IL-23 inhibitors—Janssen’s Tremfya in 2017 and Sun Pharma’s Ilumya in 2018—has substantially altered the moderate to severe psoriasis market landscape. This series includes three waves that track the awareness, trial, and usage of AbbVie’s Skyrizi following its May 2019 launch for psoriasis. In addition, the series examines physician-anticipated trends in moderate to severe psoriasis treatment and, in particular, Skyrizi’s uptake; it also assesses AbbVie’s promotional efforts around the drug.


  • How quickly are U.S. dermatologists adopting Skyrizi, and what percentage of their psoriasis patients do they consider candidates for the drug?
  • When and for which patients are dermatologists prescribing Skyrizi, what are the reasons for prescribing, and how satisfied are they with the drug?
  • How do prescribers and nonprescribers of Skyrizi compare across key metrics?
  • What promotional messages and activities are AbbVie employing in support of the launch of Skyrizi?


United States

Primary Research

Survey of 75 U.S. dermatologists for each wave

Key metrics included

Unaided and aided awareness of Skyrizi

Familiarity with and impressions of Skyrizi

Prescriber and nonprescriber profiles

Willingness to prescribe Skyrizi

Performance of Skyrizi on key attributes

Sales representative visit frequency, reach, and effectiveness

Benchmarking against previously launched psoriasis agents


Emerging Therapies captures U.S. physicians’ awareness, perceptions, and usage of the launched product at one, six, and twelve months postlaunch, as well as the current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, benchmarking against other launched agents, along with statistical comparative analysis with prior waves so that marketers can track and optimize the effectiveness of their launch strategy or fine-tune their product positioning to counter its impact on their brand’s share.

Table of contents

  • Psoriasis - Emerging Therapies - Skyrizi Launch Tracking Wave 2 (US)
    • Psoriasis Emerging Therapies Skyrizi US Wave 2 (February 2020)

Author(s): Yingdee Unhavaithaya

Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis.

Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials progression.  He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing opportunities.  Yingdee received his Ph.D. in cell biology from the University of Massachusetts Medical School, and a B.S. in biology from the University of Pittsburgh at Greensburg.

Related Reports

Psoriasis - Current Treatment - Treatment Algorithms - Claims Data Analysis: Adult Psoriasis - Refreshed Dashboard 2021 (US)

Adult psoriasis represents an increasingly lucrative market for biologics to treat the moderate to severe population, for whom conventional systemic and topical treatments alone are not sufficient....

View Details

Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF

View Details

Psoriasis - Current Treatment - Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management o...

View Details

Psoriasis | Disease Landscape and Forecast | G7 | 2020

The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier posit...

View Details